KCM
BTAI icon

Kennedy Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

Kennedy Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,533
Closed -$1.18M – 630
2021
Q2 		$1.18M Sell
2,533
-53
-2% -$28.9K 0.03% 514
2021
Q1 		$1.79M Buy
+2,586
New +$2.08M 0.04% 519

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Kennedy Capital Management's BTAI Position: Q3 2021 in Review

Kennedy Capital Management sold out of BioXcel Therapeutics (BTAI) in Q3 2021, closing a stake of 2,533 shares — an estimated $1.18M sold.

Kennedy Capital Management first reported a position in BTAI in Q1 2021 and held it in 2 quarters. The position peaked at $1.79M in Q1 2021. 103 funds tracked by Wall St. Rank hold BTAI as of Q3 2021.

  • Kennedy Capital Management reported no remaining BioXcel Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Kennedy Capital Management sold 2,533 BioXcel Therapeutics shares in Q3 2021, an estimated $1.18M.
  • Kennedy Capital Management first reported a position in BioXcel Therapeutics in Q1 2021 and held it in 2 quarters.
  • Kennedy Capital Management's BioXcel Therapeutics position peaked at $1.79M in Q1 2021.
  • 103 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2021.

Based on Kennedy Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.